| MUSC Foundation for Research Development Patent applications |
| Patent application number | Title | Published |
|---|
| 20120122870 | Treatment Of Ischemia-Reperfusion Injury - Ischemia-reperfusion injury remains a primary cause of morbidity and mortality in individuals who experience disruption of normal blood flow to one or more major organs. For example, there are no clinically proven strategies that prevent acute renal failure following cardiac surgery. The present invention provides a variety of methods for the treatment or prevention of ischemia-reperfusion injury. In one aspect of the invention, a method for treating or preventing ischemia-reperfusion injury includes administering to a subject an effective amount of a sphingosine kinase inhibitor. Sphingosine kinase inhibitors are very effective in the protection against IR-induced acute renal failure and liver failure. Moreover, the effects occur very early after administration, requiring only a very short time of treatment. Toxicology studies with sphingosine kinase inhibitors demonstrate that they have low toxicity, even in long-term treatment. | 05-17-2012 |
| 20120022343 | SYSTEMS AND METHODS FOR DETECTING DECEPTION BY MEASURING BRAIN ACTIVITY - Methods for determining whether the brain activity of a human subject in response to a stimulus of interest or question of interest is characteristic of a state of interest, such as a deceptive state or a truthful state, are disclosed. Some methods include the use of control questions, including truthful control questions and deceptive control questions, to provide bases for comparison for responses to stimuli of interest or questions of interest. In some methods, brain maps are generated and compared. Also disclosed are systems for detecting deception by measuring brain activity. | 01-26-2012 |
| 20120015872 | COMPLEMENT RECEPTOR 2 TARGETED COMPLEMENT MODULATORS - Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system. | 01-19-2012 |
| 20120015871 | COMPLEMENT RECEPTOR 2 TARGETED COMPLEMENT MODULATORS - Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system. | 01-19-2012 |
| 20120014952 | COMPLEMENT RECEPTOR 2 TARGETED COMPLEMENT MODULATORS - Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system. | 01-19-2012 |
| 20120010094 | DETECTING AND MONITORING LEFT VENTRICULAR HYPERTROPHY AND CONGESTIVE HEART FAILURE BY PROFILING BIOMARKERS - Disclosed herein are methods of detecting, monitoring, and predicting left ventricular hypertrophy, congestive heart failure and related conditions by profiling biomarkers. | 01-12-2012 |
| 20110318758 | HUMAN MONOCLONAL ANTIBODIES AND METHODS FOR PRODUCING THE SAME - The present invention provides for methods of producing human monoclonal antibodies against a wide variety of antigens including bacterial and viral antigens, as well as tumor antigens, and various autoantigens. Also provided are the antibodies themselves, nucleic acids encoding such antibodies, cells producing such antibodies, and methods of using such antibodies for diagnostic assays and passive immunity against disease states such as infection and cancer. | 12-29-2011 |
| 20110264156 | DEVICES AND METHODS FOR TREATMENT OF MYOCARDIAL CONDITIONS - Provided are devices and methods for treating a subject having a myocardial condition using sub-threshold electrical stimulation. | 10-27-2011 |
| 20110263664 | Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer - The disclosure relates to inhibitors of Pim-1 and/or Pim-2 protein kinase, to compositions comprising one or more inhibitors of Pim-1 and/or Pim-2 protein kinase, and to methods for treating cancer. | 10-27-2011 |
| 20110245188 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES OR CONDITIONS - The present invention relates to methods and compositions of treating or preventing inflammatory diseases or conditions in a patient comprising administering to the patient a therapeutically effective amount of a composition comprising a glutathione donor, 5-amino 4-imidazolecarboxamide ribotide (AICAR), a 3-hydroxy-3-methylgluatryl-coenzymeA (HMG-CoA) reductase inhibitor, D-threo-1-Phenyl-2-decanoylamino-3-morpholino-1-propanol HCl (D-PDMP), and/or 1,5-(butylimino)-1,5-dideoxy-D-glucitol (Miglustat), or derivatives thereof. | 10-06-2011 |
| 20110237662 | Use of Statins to Inhibit Inflammation and Vascular Disease - The current invention discloses novel methods for the inhibition of inducible nitric oxide synthesis (iNOS) and the production of NO. Methods of inhibiting the induction of proinflammatory cytokines are also described. Methods of treating various disease states, such as X-linked adrenoleukodystrophy, multiple sclerosis, Alzheimer's and septic shock using inhibitors of iNOS and cytokine induction are disclosed. The inhibitors include the exemplary compounds lovastatin, a sodium salt of phenylacetic acid (NaPA), FPT inhibitor II, N-acetyl cysteine (NAC), and cAMP. | 09-29-2011 |
| 20110117560 | ASSESSING LEFT VENTRICULAR REMODELING VIA TEMPORAL DETECTION AND MEASUREMENT OF microRNA IN BODY FLUIDS - Disclosed are methods and materials for assessing cardiac failure, cardiac hypertrophy, and left ventricular remodeling using microRNA levels. The level of microRNAs can be measured in a body fluid, such as plasma and serum. | 05-19-2011 |
| 20110059173 | COMPOSITIONS AND METHODS FOR PROMOTING WOUND HEALING AND TISSUE REGENERATION - Provided herein are compositions and methods for use in promoting wound healing and tissue regeneration following tissue injury in a subject. | 03-10-2011 |
| 20110034419 | Cardioprotective Drugs and Diagnostics for Assessing Risk of Cardiovascular Disease - Disclosed are methods of diagnosing cardiovascular disease comprising measuring sphingolipids. Also disclosed are methods of predicting cardiovascular disease comprising measuring sphingolipids. Also disclosed are methods of identifying subjects at risk of developing cardiovascular disease comprising measuring sphingolipids. | 02-10-2011 |
| 20100291188 | Periostin Inhibitory Compositions for Myocardial Regeneration, Methods of Delivery, and Methods of Using Same - We claim the compositions of matter and methods described herein. | 11-18-2010 |
| 20100286762 | Compositions and Methods for Ameliorating Clinical Electrical Disturbances - Disclosed are compositions and methods for the use of ACT1 peptide or other approaches to targeting the ZO-1 PDZ2 domain to treat non-injury related disturbance to electrical activation and ion transients in organ systems. | 11-11-2010 |
| 20100015651 | Predicting Heart Failure Following Myocardial Infarction by Protease and Protease Inhibitor Profiling - Disclosed herein are methods of detecting or predicting diastolic heart failure in a subject, comprising identifying a profile of matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) from a body fluid of the subject that is associated herein with the existence of likely development of left ventricular dilation (LVD). | 01-21-2010 |
| 20090192120 | INHIBITORS OF NITRIC OXIDE SYNTHASE - The current invention discloses novel methods for the inhibition of inducible nitric oxide synthesis (iNOS) and the production of NO. Methods of inhibiting the induction of proinflammatory cytokines are also described. Methods of treating various disease states, such as X-linked adrenoleukodystrophy, multiple sclerosis, Alzheimer's and septic shock using inhibitors of iNOS and cytokine induction are disclosed. The inhibitors include the exemplary compounds lovastatin, a sodium salt of phenylacetic acid (NaPA), FPT inhibitor II, N-acetyl cysteine (NAC), and cAMP. | 07-30-2009 |
| 20090111812 | METHODS FOR TREATING INFLAMMATORY DISORDERS - The present invention relates generally to the fields of molecular biology. More particularly, it concerns materials and methods for the treatment of nitric oxide and cytokind mediated disorders. In a preferred embodiment, PDMP may be used to inhibit the expression of iNOS and pro-inflammatory cytokines such as TNFα and IL1β. | 04-30-2009 |
| 20080275104 | METHODS OF TREATING JUVENILE TYPE 1 DIABETES MELLITUS - The present disclosure describes methods for treating Type 1 diabetes mellitus in juveniles. This treatment of Type 1 diabetes is achieved by administering one or more therapeutic agents to a juvenile in need, wherein the therapeutic agent is, for example, a competitive inhibitor of mevalonate synthesis, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, or an inducer of AMP protein kinase (AMPK) activity. In certain embodiments, juveniles with Type 1 diabetes are treated with an HMG-CoA reductase inhibitor such as a statin. | 11-06-2008 |
| 20080233563 | Enhanced Detection of Rna Using a Panel of Truncated Gene-Specific Primers for Reverse Transcription - The present invention provides truncated gene-specific primers in panels that can be used during the reverse transcription step of RT-PCR to increase signal detection of cancer gene markers in a tissue sample. Also provided are forward and reverse primers for RT-PCR. Methods of using the primers are also provided. | 09-25-2008 |
| 20080227846 | METHODS OF TREATING JUVENILE TYPE 1 DIABETES MELLITUS - The present disclosure describes methods for treating or preventing Type 1 diabetes mellitus in juveniles, particularly in juveniles newly diagnosed with Type 1 diabetes. This prevention or treatment of Type 1 diabetes is achieved by administering one or more therapeutic agents to a juvenile in need, wherein the therapeutic agent is, for example, a competitive inhibitor of mevalonate synthesis, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, or an inducer of AMP protein kinase (AMPK) activity. In certain embodiments, juveniles with Type 1 diabetes are treated with an HMG-CoA reductase inhibitor such as a statin, thereby decreasing the destruction of islet cells, or maintaining endogenous insulin production, in the juvenile. | 09-18-2008 |
